Coherus Oncology (CHRS) EBIT (2013 - 2026)
Coherus Oncology recorded quarterly EBIT of -$36.2 million in Q1 2026, down 137.35% quarter-over-quarter from $96.8 million in Q4 2025, and up 20.43% year-over-year from -$30.0 million in Q1 2025.
Coherus Oncology's EBIT history runs 14 years deep, the most recent figure standing at -$36.2 million for Q1 2026.
- In Q1 2026, EBIT rose 20.43% year-over-year to -$36.2 million; the TTM figure through Mar 2026 stood at -$29.2 million (up 83.55% YoY), while the FY2025 annual figure was -$38.5 million, up 80.74% from the prior year.
- EBIT came in at -$36.2 million for Q1 2026 at Coherus Oncology, down from $96.8 million in the prior quarter.
- In the past five years, EBIT ranged from a high of $96.8 million in Q4 2025 to a low of -$80.9 million in Q1 2022.
- A 5-year average of -$43.2 million and a median of -$45.4 million in 2025 frame the typical range for EBIT.
- Across the five-year window, EBIT tumbled 145.37% in 2022 and soared 313.29% in 2025, its largest moves.
- Coherus Oncology's EBIT stood at -$51.5 million in 2022, then plunged by 33.81% to -$68.9 million in 2023, then surged by 34.14% to -$45.4 million in 2024, then jumped by 313.29% to $96.8 million in 2025, then sank by 137.35% to -$36.2 million in 2026.
- According to Business Quant data, EBIT over the past three periods registered -$36.2 million, $96.8 million, and -$44.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Coherus Oncology | 216.87 Mn | 49.83 Mn | 8.50 Mn | -36.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -36.15 Mn |
| Dec 31, 2025 | 96.80 Mn |
| Sep 30, 2025 | -44.33 Mn |
| Jun 30, 2025 | -45.49 Mn |
| Mar 31, 2025 | -45.44 Mn |
| Dec 31, 2024 | -45.38 Mn |
| Sep 30, 2024 | -46.86 Mn |
| Jun 30, 2024 | -39.63 Mn |
| Mar 31, 2024 | -67.79 Mn |
| Dec 31, 2023 | -68.91 Mn |
| Sep 30, 2023 | -32.01 Mn |
| Jun 30, 2023 | -34.54 Mn |
| Mar 31, 2023 | -67.75 Mn |
| Dec 31, 2022 | -51.49 Mn |
| Sep 30, 2022 | -80.45 Mn |
| Jun 30, 2022 | -44.01 Mn |
| Mar 31, 2022 | -80.93 Mn |
| Dec 31, 2021 | -39.55 Mn |
| Sep 30, 2021 | -32.79 Mn |
| Jun 30, 2021 | -24.16 Mn |
| Mar 31, 2021 | -167.36 Mn |
| Dec 31, 2020 | 16.43 Mn |
| Sep 30, 2020 | 33.72 Mn |
| Jun 30, 2020 | 65.31 Mn |
| Mar 31, 2020 | 40.87 Mn |
| Dec 31, 2019 | 45.03 Mn |
| Sep 30, 2019 | 51.84 Mn |
| Jun 30, 2019 | 27.49 Mn |
| Mar 31, 2019 | -16.60 Mn |
| Dec 31, 2018 | -60.50 Mn |
| Sep 30, 2018 | -56.97 Mn |
| Jun 30, 2018 | -44.91 Mn |
| Mar 31, 2018 | -42.03 Mn |
| Dec 31, 2017 | -46.47 Mn |
| Sep 30, 2017 | -56.62 Mn |
| Jun 30, 2017 | -56.64 Mn |
| Mar 31, 2017 | -72.42 Mn |
| Dec 31, 2016 | -73.46 Mn |
| Sep 30, 2016 | 84.62 Mn |
| Jun 30, 2016 | -62.74 Mn |
| Mar 31, 2016 | -64.35 Mn |
| Dec 31, 2015 | -52.21 Mn |
| Sep 30, 2015 | -71.22 Mn |
| Jun 30, 2015 | -58.90 Mn |
| Mar 31, 2015 | -36.75 Mn |
| Dec 31, 2014 | -26.56 Mn |
| Sep 30, 2014 | -6.42 Mn |
| Jun 30, 2014 | -17.94 Mn |
| Mar 31, 2014 | -13.76 Mn |
| Dec 31, 2013 | -10.49 Mn |
| Sep 30, 2013 | -6.78 Mn |